Aptevo Therapeutics
APVO
4 hedge funds and large institutions have $45.9K invested in Aptevo Therapeutics in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and 3 closing their positions.
101% more capital invested
Capital invested by funds: $22.8K → $45.9K (+$23.1K)
0.02% more ownership
Funds ownership: 0% → 0.03% (+0.02%)
20% less funds holding
Funds holding: 5 → 4 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Birchview Capital
Burlington,
Vermont
|
+$101K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$33K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.4K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
+$5.65K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$12.2K |
| 2 |
CS
Clear Street
New York
|
-$3.25K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.09K |
| 4 |
Morgan Stanley
New York
|
-$4 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BC
1
Birchview Capital
Burlington,
Vermont
| $30.5K | +$101K | +556 | New |
|
|
2
Osaic Holdings
Scottsdale,
Arizona
| $9.91K | +$33K | +181 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $3.64K | +$10.4K | +57 | +633% |
|
|
SS
4
SBI Securities
Tokyo,
Japan
| $1.79K | +$5.65K | +31 | +1,550% |
|
|
5
Bank of America
Charlotte,
North Carolina
| $9 | -$1.09K | -6 | Closed |
|
6
BlackRock
New York
| $3 | – | – | – |
|
|
DB
7
Danske Bank
Copenhagen K,
Denmark
| $3 | – | – | – |
|
|
8
Geode Capital Management
Boston,
Massachusetts
| – | -$12.2K | -29 | Closed |
|
|
CS
9
Clear Street
New York
| – | -$3.25K | -8 | Closed |
|
|
10
Morgan Stanley
New York
| – | -$4 | – | – |
|
APVO Hedge Fund Activity: Q2 2025 in Review
4 of the 7,597 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q2 2025, worth a combined $45.9K — up 101% from $22.8K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of APVO and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.
The largest buyer was Birchview Capital, opening a new position worth an estimated $101K. The largest seller was Geode Capital Management, exiting entirely with an estimated $12.2K sold.
- 4 institutional investors held Aptevo Therapeutics (APVO) as of Q2 2025, down from 5 in Q1 2025.
- Funds reported $45.9K of Aptevo Therapeutics stock for Q2 2025, up 101% quarter-over-quarter.
- 2 funds opened new Aptevo Therapeutics positions in Q2 2025 and 3 closed out, a net change of -1 holder.
- The largest Aptevo Therapeutics buyer in Q2 2025 was Birchview Capital, an estimated $101K added.
- The largest Aptevo Therapeutics seller in Q2 2025 was Geode Capital Management, an estimated $12.2K sold.
Based on aggregated 13F filings for Q2 2025.